El-Khazragy, NashwaMohammed, Hayam FathyYassin, MohamedElghoneimy, K.K.Bayoumy, WalidHewety, AmrEL Magdoub, Hekmat M.Elayat, WaelZaki, WalidSafwat, GehanMosa, MaiZedan, KhouloudSalem, SalemaBannunah, Azzah M.Mansy, Azza2020-08-122020-08-122020-08https://doi.org/10.1016/j.ygeno.2020.08.005https://t.ly/9kLRObjectives: The current study aimed to investigate the potentiality of three lncRNAs “Plasmacytoma variant translocation 1(lnc-PVT1), Taurine upregulated gene type 1(lnc- TUG1) and Maternally expressed gene 3 (lnc-MEG-3)”, to predict Cisplatin resistance in ovarian cancer (OC), in addition, to access their prognostic significance. Methods: The expression level of lncRNAs were measured in 100 formalin-fixed paraffin- embedded tissue (FFET) samples of OC patients who were treated by Cisplatin-based chemotherapy using qPCR.Results: The results showed that lnc_PVT1 was significantly higher by 2.3 folds in Cisplatin resistant tissues, while, lnc-TUG1 and lnc-MEG3 were downregulated by 1.2 and 3 folds, respectively. In addition, the three lncRNAs exhibited high sensitivity and specificity in predicting chemo-resistance and they were negatively associated with OS and progression- free survival (p<0.001). Conclusion: The lnc-PVT1, lnc-TUG1, and lnc-MEG3 transcriptome signatures could be used for predicting resistance to Cisplatin in OC patients.en-USlnc- MEG3.lnc-TUG1lnc-PVT1Cisplatin resistanceLong non-coding RNAOvarian cancerArticlehttps://doi.org/10.1016/j.ygeno.2020.08.005